Fourth Circuit to Reconsider Dismissal of Whistleblower Action Alleging Medicaid Rebate Program Fraud
- May 13, 2022
The full Fourth Circuit will reconsider the dismissal of a qui tam action alleging that Forest Laboratories (Forest), a subsidiary of Allergan plc, violated the False Claims Act (FCA) by providing false price reports to the government under the Medicaid Drug Rebate Program, causing overpayments for the company’s drugs.
ARTICLE TAGS
You must be logged in to access this content.